Agenus Inc. entered into an amendment to its senior subordinated promissory notes and warrants on June 29, 2026. The company extended the maturity of $5.09 million in 2015 Notes to February 18, 2027, and extended the expiration dates of several existing warrants to June 25, 2031. Additionally, the company issued new 2026 D Warrants to purchase 56,525 shares of common stock at an exercise price of $3.25 per share. Agenus Inc. is a biotechnology company focused on developing immuno-oncology therapies.
